How Amgen uses GPT-5

OpenAy's latest customer post drops Amgen into the growing list of large enterprises publicly leaning on GPT-5, and the pairing makes sense on paper. Amgen is one of the biggest biotech companies on earth, built on decades of drug discovery, manufacturing at scale, and mountains of regulatory paperwork. Any of those areas is exactly the kind of dense, document-heavy, deadline-driven work that a frontier language model is supposed to help with.

The blog post itself is thin on hard numbers, which is typical of OpenAI's enterprise showcases — they read more like a highlight reel than a technical teardown. Still, the choice of subject says something. Amgen isn't a startup dabbling in AI for a demo; it's a company with strict compliance requirements, FDA relationships, and a research pipeline that costs billions of dollars to run. If a company like that is willing to let OpenAI use its name in a case study, that's a signal GPT-5 is being trusted with more than internal chatbots.

What's missing from the piece is the interesting part: which teams inside Amgen are actually touching GPT-5, what guardrails are wrapped around it given the regulatory stakes of pharma, and whether this is scientific research support, clinical documentation, or something more mundane like internal knowledge search. OpenAI's enterprise stories tend to gesture at transformation without spelling out the mechanics, and this one follows that pattern closely.

That said, the direction is clear enough. Model providers want pharma as a flagship vertical because the sector has money, complexity, and a genuine need to move faster through discovery and paperwork alike. Expect more of these case studies from OpenAI as it tries to prove GPT-5 belongs in boardrooms, not just chat windows.